Citations

Showing 10 of 108104 citations.

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa).
Pomerantz, Mark M., Wang, Victoria , Lee, Gwo‐Shu Mary , Hahn, Noah M. , Jarrard, David F. , Liu, Glenn , García, Jorge A. , DiPaola, Robert S. , Freedman, Matthew L. , Kantoff, Philip W. , Xie, Wanling , Kohli, Manish , Wang, Elaine, Chen, Yu‐Hui , Carducci, Michael A. , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1540-1540

10.1200/jco.2016.34.15_suppl.1540 Get It

Patterns and predictors of BRCA 1/2 testing in young breast cancer survivors.
Rosenberg, Shoshana M. , Ruddy, Kathryn J. , Barry, William T., Sprunck, Kim, Ligibel, Jennifer A. , Domchek, Susan M. , Partridge, Ann H.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1514-1514

10.1200/jco.2016.34.15_suppl.1514 Get It

Risks of triple negative breast cancer associated with cancer predisposition gene mutations.
Akinhanmi, Margaret, Hallberg, Emily J., Moore, Raymond M. , LaDuca, Holly , Goldgar, David E. , Dolinsky, Jill S. , Couch, Fergus J. , Shimelis, Hermela , Hu, Chunling , Hart, Steven N. , Meeks, Huong , Huether, Robert , Chao, Elizabeth

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1513-1513

10.1200/jco.2016.34.15_suppl.1513 Get It

Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT).
DiGiovanni, Laura , Gaddam, Pragna, Walsh, Michael F. , Offit, Kenneth , Balmañà, Judith , Garber, Judy E. , Couch, Fergus J. , Robson, Mark E. , Domchek, Susan M.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1510-1510

10.1200/jco.2016.34.15_suppl.1510 Get It

Double blind phase III trial of effects of low dose 13-cisretinoic acid on prevention of second primaries in stages I-II head and neck cancer: A trial of the ECOG-ACRIN Cancer Research Group (C0590).
Bhatia, Aarti , Lee, Ju‐Whei , Pinto, Harlan , Jacobs, Charlotte, Arusell, Robert M., Dunphy, Eamonn P., Khandekar, Janardan D., Reiner, Seth, Báez-Díaz, Luis , Celano, Paul , Li, Yi , Pandya, Kishan J., Pinto, Harlan A. , Limburg, Paul J. , Li, Shuli , Burtness, Barbara

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 1507-1507

10.1200/jco.2016.34.15_suppl.1507 Get It

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.
Chumsri, Saranya , Sperinde, Jeff, Liu, Heshan , Moreno‐Aspitia, Alvaro , McLaughlin, Sarah A. , Winslow, John , Petropoulos, Christos J. , Chenna, Ahmed , Bates, Michael, Weidler, Jodi, Lie, Yolanda, Huang, Weidong , Perez, Edith A. , Gligorov, Joseph , Spano, Jean‐Philippe

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 603-603

10.1200/jco.2016.34.15_suppl.603 Get It

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.
Palumbo, Antonio, Chanan‐Khan, Asher , Mateos, María‐Victoria , Qi, Ming , Schecter, Jordan M. , Amin, Himal, Qin, Xiang , Deraedt, William , Ahmadi, Tahamtan , Spencer, Andrew , Sonneveld, Pieter , Weisel, Katja C , Nooka, Ajay K. , Masszi, Tamás , Beksaç, Meral , Špıčka, Ivan , Hungria, Vânia , Mark, Tomer M , Qi, Ming

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: LBA4-LBA4

10.1200/jco.2016.34.15_suppl.lba4 Get It

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
Petrylak, Daniel P. , Heijden, Michiel Simon Van Der, O’Donnell, Peter H. , Retz, Margitta, Grivas, Petros , Boyd, Zachary, Nickles, Dorothee , Hegde, Priti S., Mariathasan, Sanjeev , Rosenberg, Jonathan E , Necchi, Andrea , Loriot, Yohann , Perez‐Gracia, José Luis , Bellmunt, Joaquim , Joseph, Richard W. , Fong, Lawrence , Kadel, Edward E. , Frampton, Garrett M. , Bourgon, Richard , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 104-104

10.1200/jco.2016.34.15_suppl.104 Get It

Representation of minorities in oncology clinical trials: Review of the past 14 years.
Duma, Narjust , Aguilera, Jesus Vera, Leventakos, Konstantinos , Adjei, Alex A. , Paludo, Jonas , Wang, Yucai , Mansfield, Aaron S.

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 2533-2533

10.1200/jco.2017.35.15_suppl.2533 Get It

2533 Background: Many cancer clinical trials (CT) lack appropriate representation of specific patients populations, limiting the generalizability of the evidence obtained. Therefore, we determined the representation of ethnic minorities in oncology CT. Methods: Enrollment data from all therapeutic trials reported as completed in clinicaltrial.gov from 2003 to 2016 were analyzed. CT in rare cancers (< 1% incidence) or with recruitment outside of the US were excluded. Enrollment fraction (EF) was defined as the number of enrollees divided by the 2013 SEER database cancer prevalence. Chi-square test was used to estimate differences in categorical data. Results: Out of 1,012 CT, 310 (31%) reported ethnicity with a total of 55689 enrollees. Distribution by race and comparison with data from 1996-2002, US cancer prevalence and US census are described in the Table. Participation in CT varied significantly across ethnic groups, non-Hispanic Whites (NHW) were more likely to be enrolled in CT (EF of 1.2%) than African Americans (EF of 0.7%, p < 0.001) and Hispanics (EF of 0.4%, p<0.001). A decrease in African Americans (AA) and Hispanics (H) enrollment was observed when compared with historical data from 1996 to 2002. Hispanics were less represented in breast and prostate cancer CT contributing only to 3% and 1.5% of the study population; African Americans were less represented in lung (5.4%) and renal cell carcinoma (3%) trials. Asians were well represented and their recruitment doubled over the past 14 years (2% vs 5.3%). Conclusions: African Americans and Hispanics were less likely to be enrolled in CT. Comparing with historical data; we observed a decrease in minorities’ recruitment in the past 14 years. This change could be attributed to the increased complexity of CT and mandatory molecular testing as many minorities lack access to institutions with genetic testing capacity. Future trials should take extra measures to recruit participants that adequately represent the U.S. cancer population. [Table: see text]